Supreme Court Passes On Schering-Plough Appeal

Law360, New York (June 26, 2006, 12:00 AM EDT) -- In a move that could open the floodgates for controversial patent settlement deals between brand-name and generic drug companies, the nation’s highest court Monday turned down the U.S. Federal Trade Commission’s appeal in the closely watched Schering-Plough case.

The U.S. Supreme Court’s rejection came after months of debate between the FTC and the U.S. Solicitor General's office as to whether the justices should hear the case amid the FTC’s wider probe into anti-competitive practices in the prescription drug industry.

Christopher M. Curran, partner at White &...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.